CD38 and breast cancer: Similar results were obtained in primary CD34+CD38− cells (low miR-142) from BC CML patients compared with CD34+CD38− cells (high miR-142) from CP CML patients (Fig. 5e; Supplementary Figs. 8i, j and 9a, b, right).